We’re excited to share that research supported by our preclinical team was featured at the ASH 2025 Annual Meeting, taking place December 6–9 in Orlando, Florida, and online. The work was presented by our collaborators as part of a Nordic Eurostars consortium (Oncopeptides AB (publ), KTH Royal Institute of Technology, and Oslo University Hospital).

Poster Title:
Ex vivo expanded adaptive NK cells in combination with a bispecific NK cell engager targeting BCMA for synergistic control of multiple myeloma

This study highlights a novel humanized multiple myeloma mouse model developed and validated in our labs, enabling the evaluation of a promising combination immunotherapy: adaptive NK cells paired with a BCMA-targeting bispecific NK cell engager.

As a preclinical CRO, we’re proud to contribute translational models that help bridge the gap between discovery and clinical impact. Collaborations like this one are essential to accelerating innovation in hematologic oncology.

Eurostars is part of the European Partnership on Innovative SMEs. The partnership is co-funded by the European Union through Horizon Europe.